HIV-1-infection
Showing NaN - NaN of 8
HIV-1-infection Trial in Brazil, United States (ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3)
Not yet recruiting
- HIV-1-infection
- ChAdOx1.tHIVconsv1
- +7 more
-
San Diego, California
- +11 more
Oct 4, 2023
HIV-1-infection Trial in Worldwide (Once daily CAB tablet + RPV tablet, Long acting CAB injectable + long acting RPV injectable)
Not yet recruiting
- HIV-1-infection
- Once daily CAB tablet + RPV tablet
- Long acting CAB injectable + long acting RPV injectable
-
Atlanta, Georgia
- +11 more
Dec 13, 2022
HIV-1-infection Trial in Worldwide (Oral Lenacapavir, Oral Lenacapavir Placebo, Subcutaneous Lenacapavir)
Active, not recruiting
- HIV-1-infection
- Oral Lenacapavir
- +4 more
-
Los Angeles, California
- +74 more
Oct 17, 2022
HIV-1-infection Trial in United States (426c.Mod.Core-C4b 30 mcg, 426c.Mod.Core-C4b 100 mcg, 426c.Mod.Core-C4b 300 mcg)
Recruiting
- HIV-1-infection
- 426c.Mod.Core-C4b 30 mcg
- +3 more
-
Birmingham, Alabama
- +5 more
Jul 25, 2022
HIV/AIDS, HIV-1-infection, Osteopenia Trial in United States (Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE
Withdrawn
- HIV/AIDS
- +2 more
- Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC)
- Current tenofovir alafenamide (TAF)-containing ART regimen
-
Birmingham, Alabama
- +9 more
Mar 10, 2021
HIV-1 Reservoir in Central Nervous System of
Completed
- HIV-1-infection
-
Los Angeles, California
- +11 more
Jul 7, 2020